Actively Recruiting
Evaluating SPN-821 as an Additional Treatment for Adults With Major Depressive Disorder in a Randomized, Placebo-Controlled Study
Led by Supernus Pharmaceuticals, Inc. · Updated on 2026-10-28
230
Participants Needed
40
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of SPN-821, a novel oral drug, as an additional treatment for adults with major depressive disorder MDD. This phase 2, multicenter, randomized, double-blind, placebo-controlled study focuses on adults diagnosed with MDD who continue to experience symptoms despite stable antidepressant therapy. The study aims to assess improvements in depression severity using standardized rating scales. Participants are randomly assigned to receive either SPN-821 at a dose of 2400 mg three 800 mg tablets or matching placebo tablets, both administered twice a week alongside their current antidepressant medication. The study includes a 2-week screening period to confirm eligibility, followed by a 4-week treatment period where participants receive the assigned study tablets. After completing treatment, participants undergo a safety follow-up phone call one week later to monitor any ongoing effects. During the study, participants will have their depression symptoms evaluated using the Montgomery-sberg Depression Rating Scale MADRS and Clinical Global Impression-Severity CGI-S scale at baseline and Day 29. Safety assessments and monitoring occur throughout the trial and during the follow-up call. Overall, the study participation lasts approximately 7 weeks including screening, treatment, and follow-up to understand the impact of SPN-821 on depressive symptoms and safety in adults with MDD.
CONDITIONS
Brief Title
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Research Team
G
Gianpiera Ceresoli-Borroni, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here